AMRX
Amneal Pharmaceuticals, Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
Momentum inputs (comparable managers):
holder breadth +30.0% ·
share flow +2.4% ·
net new positions +20.0%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 101 | -4 | 106.56M | $1.84B | +7 | −10 |
| Q1 2026 | 107 | -1 | 100.53M | $1.25B | +9 | −11 |
| Q4 2025 | 109 | 0 | 106.30M | $1.34B | +1 | — |
| Q3 2025 | 18 | 0 | 61.16M | $612.26M | — | — |
| Q2 2025 | 15 | -1 | 52.63M | $425.79M | — | −1 |
| Q1 2025 | 13 | +3 | 21.14M | $177.14M | +3 | — |
| Q4 2024 | 10 | -1 | 20.64M | $163.48M | — | −1 |
| Q3 2024 | 10 | 0 | 16.87M | $140.36M | +2 | −2 |
| Q2 2024 | 10 | — | 16.56M | $105.19M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Citadel Advisors ✦ | 7.49M | -16.6% | $62.78M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 2 | Citadel Advisors ✦ | 7.49M | -16.6% | $62.78M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 3.83M | +0.3% | $32.06M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 3.83M | +0.3% | $32.06M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 5 | State Street Global Advisors ✦ (passive) | 3.69M | -0.2% | $30.93M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 6 | Millennium Management ✦ | 2.09M | +57.6% | $17.49M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 7 | Arrowstreet Capital ✦ | 1.79M | +16.4% | $15.03M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 8 | AQR Capital Management ✦ | 745.48K | +121.3% | $6.25M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 9 | AQR Capital Management ✦ | 745.48K | +121.3% | $6.25M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 10 | AQR Capital Management ✦ | 745.48K | +121.3% | $6.25M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 11 | AQR Capital Management ✦ | 745.48K | +121.3% | $6.25M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 12 | AQR Capital Management ✦ | 745.48K | +121.3% | $6.25M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 13 | Renaissance Technologies ✦ | 624.70K | -9.0% | $5.23M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 14 | Point72 Asset Management ✦ | 446.00K | New | $3.74M | 0.0% | New | 1 | SEC ↗ |
| 15 | Two Sigma Investments ✦ | 167.70K | New | $1.41M | 0.0% | New | 1 | SEC ↗ |
| 16 | T. Rowe Price ✦ | 126.68K | +30.3% | $1.06M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 17 | Wellington Management ✦ | 70.05K | -5.4% | $587,036 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 18 | Wellington Management ✦ | 70.05K | -5.4% | $587,036 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 19 | Wellington Management ✦ | 70.05K | -5.4% | $587,036 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 20 | Wellington Management ✦ | 70.05K | -5.4% | $587,036 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 21 | Gotham Asset Management ✦ | 52.67K | -40.1% | $441,366 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 22 | D. E. Shaw & Co. ✦ | 15.84K | New | $132,706 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Point72 Asset Management | $3.74M | 0.0% |
| Two Sigma Investments | $1.41M | 0.0% |
| D. E. Shaw & Co. | $132,706 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 314 holders, 158.91M shares, $1.92B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 50.00K sh · $882,000
Officer · 146.40K sh · $2.56M
Officer · 210.00K sh · $3.65M
Officer · 6.61K sh · $117,050
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
17.6% of class · View original SEC filing ↗
8.4% of class · View original SEC filing ↗
9.4% of class · View original SEC filing ↗